SBIR/STTR Research Award

Click Chemistry for Immobilized Bone Morphogenetic Protein

Award identifier 54350eb01e223af997074dffd280bad262c98845102be5906d667c749c0a0c0fAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$240,279

Program and phase

SBIR · Phase I

Award year

2006

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
AFFINERGY, LLC
Proposal award date
Not reported
Contract end date
Not reported
UEI
YJQ6K1QMS488
Solicitation number
PHS2006-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): There are over 6.3 million fractures each year in the United States of which approximately 700,000 are difficult to heal. The available treatment options for fractures that do not heal or are slow to heal are limited. Bone morphogenetic proteins are growth factors that stimulate new bone production and have received FDA approval for bone fracture repair and spinal fusion. For most clinically approved uses of BMPs, a resorbable collagen sponge is used as the delivery matrix to retain BMP at the site of repair. Low affinity of BMP for the collagen results in the rapid diffusion of BMP and as a result, supraphysiological levels of BMP are required to promote healing. Affinergy develops peptidic macromolecules, interfacial biomaterials (IFBMs) that modulate the critical interface between biological surfaces to initiate and specify interfacial biologic activities. The IFBMs under investigation are composed of different peptide modules that have affinity for BMP and the collagen sponge. A limitation of the technology is the ability to construct many different IFBMs to facilitate rapid screening for subsequent in vivo evaluation. [3 + 2] cyclo-addition or "click chemistry" will be used to prepare IFBMs since this takes advantage of our modular approach and allows for higher total yields through the coupling of shorter peptides (<25 mers). As a model system we will identify, synthesize, and characterize IFBMs that bind a regenerated collagen sponge and a growth factor for sustained release of Bone Morphogenetic Protein (BMP) to improve bone healing at a fracture site. The specific aims are: Aim 1: Optimize the reaction conditions for coupling peptides of varying molecular weights and sequences using click-chemistry Aim 2: Screen a library of synthesized IFBMs from peptides identified using phase display and determine binding affinity in vitro to BMP-2 Aim 3: Evaluate the in-vitro ability of BMP-IFBM coated collagen sponges with varying BMP affinities to induce osteoblast differentiation in a C3H10T1/2 mouse mesenchymal cell line The goal of this SBIR is to demonstrate that IFBMs can be used with a resorbable material to control the delivery of growth factors to bone injuries with the intent of improving healing and clinical outcomes. There are over 6.3 million fractures each year in the United States of which approximately 700,000 are difficult to heal. Bone morphogenetic proteins (BMPs) are growth factors that stimulate new bone production and have received FDA approval. Currently, a resorbable collagen sponge is used as a delivery matrix for BMP. Low affinity of BMP for the sponge results in poor delivery profiles requiring supraphysiological levels of BMP to promote healing. In this proposal, we describe a novel peptide based approach to enhance the affinity of BMP- 2 to the sponge and postulate that this improvement will result in sustained release of BMP resulting in improved bone healing.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

75 SBIR/STTR records share this UEI (2005–2023). Reported award amounts total $59,804,968. Reported amounts are not federal obligations.

Phases: Phase I, Phase II, Phase II – Direct to Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.